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Background
A number of factors play a role in market access of orphan
drugs, such as the extent to which an orphan drug meets a
medical need; existence of alternative health technologies;
disease prevalence; number of orphan drug indications;
and added clinical benefit of the orphan drug. How can
these factors be taken into account in market access deci-
sions given that there is uncertainty over which factors
matter and given that not all orphan drugs meet these
criteria to the same degree [1]?
Materials and methods
Multi-criteria decision analysis is a technique which
enables decision makers to consider multiple criteria in
market access decisions. This technique brings together an
expert panel which identifies the relevant decision-making
criteria and their relative importance. The panel then
quantifies the extent to which an orphan drug attains each
criterion. The scores of the orphan drug on the different
criteria are weighted according to their relative importance
and an overall score for the orphan drug is computed.
Drugs are ranked according to their score and resources
are allocated based on this ranking until the budget is
exhausted.
Results
To the best of the author’s knowledge, no multi-criteria
decision analysis has in practice been carried out for
orphan drugs. However, the following paragraphs illustrate
this technique by proposing and justifying three criteria
that could be considered in orphan drug market access
decisions, i.e. disease prevalence, existence of alternative
health technologies, and repurposing.
With respect to prevalence, an economic rationale sug-
gests that prices of orphan drugs used for rare diseases
with higher prevalence should be lower than prices of
orphan drugs used for rare diseases with lower prevalence.
Similarly, the price of orphan drugs should reflect the
combined prevalence across its indications. The existence
of alternative health technologies is a second criterion to
consider in market access decisions in the light of the
impact of competitive pressures on orphan drug pricing.
Finally, orphan drugs which were originally developed for
a common disease, but later repurposed for a rare disease
are likely to have incurred lower costs of research and
development and, therefore, should claim a lower price
than an orphan drug which has been developed uniquely
to treat a rare disease.
Conclusions
The use of multi-criteria decision analysis would enhance
objectivity and transparency of market access decisions for
orphan drugs by taking into account societal preferences
about orphan drugs for rare diseases.
Published: 22 November 2012
Reference
1. Simoens S, Dooms M: Market access of orphan drugs: one size fits all?
Hospital Pharmacy Europe 2012, 62:59-63.
doi:10.1186/1750-1172-7-S2-A26
Cite this article as: Simoens: Market access of orphan drugs and the
role of multi-criteria decision making. Orphanet Journal of Rare Diseases
2012 7(Suppl 2):A26.
Correspondence: Steven.simoens@pharm.kuleuven.be
Research Centre for Pharmaceutical Care and Pharmaco-economics, KU
Leuven, Leuven, Belgium
Simoens Orphanet Journal of Rare Diseases 2012, 7(Suppl 2):A26
http://www.ojrd.com/content/7/S2/A26
© 2012 Simoens,; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
